• October 7, 2014

    Levofloxacin monotherapy is highly effective in community-acquired pneumonia
    Levofloxacin is one of the three respiratory fluoroquinolones that are recommended for empirical treatment of a wide range of patients with community-acquired pneumonia (CAP).

    It is a second generation fluoroquinolone and compared with the first generation products has improved efficacy against Gram-positive microorganisms (particularly S. pneumoniae, including penicillin resistant strains, and macrolides) and against atypical pathogens.

    In vitro levofloxacin shows antibacterial activity against most of the Gram-positive and Gram-negative organisms associated with CAP, as well as against atypical bacteria (M. pneumoniae, C. pneumonia, Legionella spp.).

    All beta-lactam antibiotics are ineffective against the above noted atypical microorganisms. In contrast, respiratory quinolones such as levofloxacin have the highest activity against these pathogens, followed by tetracyclines and macrolides

    Levofloxacin shows good in vitro activity against H. influenzae (a frequent cause of CAP in smokers and patients with COPD) and M. catarrhalis (including beta-lactamase producing strains) and against methicillin- or oxacillin-susceptible strains of S. aureus.

    Levofloxacin is approved for the treatment of systemic infections caused by P. aeruginosa.

    After oral administration, this antibiotic has a good bioavailability in the tissue (almost 100%), and reaches peak tissue concentration after 3 hours. Its long half-life allows for convenient once-daily dosing.

    Comparative randomized multicenter studies have shown that the levofloxacin has good clinical and bacteriological efficacy in the treatment of mild, moderate and severe CAP in immunocompetent adult patients – a clinical response is achieved in> 90% of the patients with low frequency of recurrence of the disease after the end of treatment .

    Levofloxacin administered orally (at a dose of 500 mg once daily for a period of 7 to 14 days) has similar effectiveness to amoxicillin/clavulanic acid in elderly patients with mild CAP.

    In hospitalized patients with severe CAP treatment with the fluoroquinolone (intravenous and then oral) is more effective than intravenous therapy with ceftriaxone and/or cefuroxime for achieving clinical recovery and bacteriological eradication.

    In most CAP cases once-daily dose of levofloxacin achieved equal serum levels after oral or intravenous administration.

    Advantages of levofloxacin:

    – Favorable pharmacokinetics allowing once-daily dosing

    – Broad antibacterial spectrum in in vitro conditions

    – Good efficacy profile established in clinical studies

    – Good tolerability profile

    Tchaikapharma High Quality Medicines Inc. offers Levofloxacin on the Bulgarian market under the following trade name:

    Levor 500 mg x 10 tabl. – BGN 14.99

  • September 24, 2012

    Mr. Georgi Georgiev, Chairman, Town Council of Slivnitsa Municipality, greeted Prof. Mladen Grigorov, Chairman of the Bulgarian Monuments of Glory Foundation and Prof. Toni Vekov, Member of the Council of Directors, TchaikaPharma High Quality Medicines on the occasion of the National Unification Day – the 6th of September. Mr. Georgiev expressed his gratitude for the monument built in commemoration of the people who lost their lives in the Serbian-Bulgarian War and thanked them for their patriotic deed.

    You can read the full text of the letter:

    Town council – Slivnitsa Municipality
    2200 Slivnitsa, Saedinenie sq. №1


    Prof. Mladen Grigorov
    Bulgarian Monuments Glory Foundation
    Commercial League

    Prof. Toni Vekov
    Member of Council of Directors
    TchaikaPharma High Quality Medicines



    I would like to extend my warmest greetings on the occasion of the 6th of September – the Unification Day of Bulgaria.

    The Bulgarian people have a glorious history and you are among the contemporary history makers. Love to one’s country is measured not only by paying tribute to its heroes but by one’s deeds.

    You are an example of real patriotism, professionalism and social responsibility and all that complemented by deep humanism and nobility.

    Building a monument in commemoration of the people who lost their lives in the Serbian-Bulgarian War is not only a patriotic deed but also a way of educating young people to remember their history and take pride in their past.

    Your deed only proves that all Bulgarians who died in the Serbian-Bulgarian War did it for a good cause.

    I am proud of such patriots like you.

    I wish you the best of luck in your personal and professional lives!

    Georgi Georgiev

    Slivnitsa Town Council

  • August 3, 2012

    Tchaikapharma High Quality Medicines Inc. was acknowledged for a consecutive time for its contribution to the development of the pharmaceutical sector in Bulgaria. The Chairman of the Bulgarian Pharmaceutical Union, Miroslav Nenchev, sent a thank you letter to Tchaikapharma after the completion of the Bulgarian Pharmaceutical Days 2012 Forum. In it he underlines the assistance provided by the pharmaceutical manufacturer in the organization of this important event and expresses his assurance that the fruitful cooperation between both organizations will continue in the future. The full text of the letter is available at:


    Dear colleagues,

    I would like to thank you on behalf of the Management Board of the Bulgarian Pharmaceutical Union for your participation in one of the most significant events of the pharmaceutical sector – the Bulgarian Pharmaceutical Days 2012.

    The event conducted under the motto “Equal access to medicines and pharmaceutical care” gathered together more than 1800 pharmacists from all over the country as well as academics and representatives of the judicial and legislative branches.

    Your support was of great importance for making this event a success.

    All positive comments about your company made by the participants makes us confident that the fruitful cooperation between you and the Bulgarian Pharmaceutical Union will continue in the future, especially in the area of developing and carrying out projects related to continued medical education.

    Sincerely yours,

    Miroslav Nenchev, MPharm
    Chairman of Management Board
    Bulgarian Pharmaceutical Union

  • July 16, 2012

    For the sixth consecutive year the Bulgarian Pharmaceutical Union held the Bulgarian Pharmaceutical Days under the motto “Equal Access to Medicines and Pharmaceutical care”. The event was attended by 54 companies working in the area of developing medications and food supplements, as well as more than 1800 pharmacists, representatives of the executive and legislative authorities, professors from faculties of Pharmacy of the Medical Universities in Sofia, Plovdiv and Varna.

    During the ball some pharmacists were presented with annual award of the Bulgarian Pharmaceutical Union, with Tchaikapharma receiving in the category “Prescription Drugs” the highest recognition for its newest product – Co-Irbesso.

    Co-Irbesso film-coated tablets 150/12.5 and 300/12.5 is a medical product for treating essential hypertonia with no analogue on the Bulgarian market and great hopes to be well accepted by patients.

    At this most important to the pharmaceutical society event of the year, Tchaikapharma presented its newest high-quality medical products, affordable for every patient.

  • February 28, 2012

    This content is currently not available in English.